[go: up one dir, main page]

WO2002046466A3 - Complexes de polypeptides de brca et de stat et procedes d'utilisation dans la detection et le traitement du cancer - Google Patents

Complexes de polypeptides de brca et de stat et procedes d'utilisation dans la detection et le traitement du cancer Download PDF

Info

Publication number
WO2002046466A3
WO2002046466A3 PCT/IB2001/002797 IB0102797W WO0246466A3 WO 2002046466 A3 WO2002046466 A3 WO 2002046466A3 IB 0102797 W IB0102797 W IB 0102797W WO 0246466 A3 WO0246466 A3 WO 0246466A3
Authority
WO
WIPO (PCT)
Prior art keywords
brca
amount
stat
activity
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2001/002797
Other languages
English (en)
Other versions
WO2002046466A2 (fr
Inventor
Sigridur Valgeirsdottir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ICELAND GENOMICS Corp
Original Assignee
ICELAND GENOMICS Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICELAND GENOMICS Corp filed Critical ICELAND GENOMICS Corp
Priority to AU2002233572A priority Critical patent/AU2002233572A1/en
Publication of WO2002046466A2 publication Critical patent/WO2002046466A2/fr
Publication of WO2002046466A3 publication Critical patent/WO2002046466A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé d'inhibition de prolifération cellulaire dépendant d'un complexe BRCA/STAT. Le procédé consiste à mettre en contact une cellule contenant BRCA/STAT avec une quantité efficace et suffisante d'un composé modulant le complexe BRCA/STAT en vue de moduler la quantité ou l'activité d'un complexe BRCA/STAT dans la cellule. L'invention concerne aussi un procédé visant à réduire la gravité d'un cancer. Ce procédé consiste à administrer à un sujet une quantité efficace et suffisante d'un composé modulant le complexe BRCA/STAT en vue de moduler la quantité ou l'activité d'un complexe BRCA/STAT de cellules cancéreuses chez le sujet. L'invention concerne aussi des procédés visant à détecter le risque que présente un patient de développer un cancer du sein. Dans un mode de réalisation, le procédé consiste à détecter une quantité ou une activité d'un complexe BRCA/STAT dans un échantillon prélevé sur un sujet présumé atteint de cancer du sein, et à comparer ladite quantité ou activité du complexe BRCA/STAT de l'échantillon à une quantité ou activité provenant d'un échantillon de référence, une différence de quantité ou d'activité entre l'échantillon et l'échantillon de référence indiquant la présence d'un cancer du sein ou le risque de développer un tel cancer. L'invention concerne aussi des procédés permettant de pronostiquer la gravité ou la progression d'un cancer du sein.
PCT/IB2001/002797 2000-12-04 2001-12-04 Complexes de polypeptides de brca et de stat et procedes d'utilisation dans la detection et le traitement du cancer Ceased WO2002046466A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002233572A AU2002233572A1 (en) 2000-12-04 2001-12-04 Complexes of brca and stat polypeptides and methods of use in the detection and treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25148400P 2000-12-04 2000-12-04
US60/251,484 2000-12-04

Publications (2)

Publication Number Publication Date
WO2002046466A2 WO2002046466A2 (fr) 2002-06-13
WO2002046466A3 true WO2002046466A3 (fr) 2003-02-13

Family

ID=22952160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/002797 Ceased WO2002046466A2 (fr) 2000-12-04 2001-12-04 Complexes de polypeptides de brca et de stat et procedes d'utilisation dans la detection et le traitement du cancer

Country Status (2)

Country Link
AU (1) AU2002233572A1 (fr)
WO (1) WO2002046466A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176303B2 (en) 2003-11-06 2007-02-13 Isis Pharmaceuticals, Inc. Modulation of STAT5 expression
JP2009502913A (ja) * 2005-07-27 2009-01-29 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 調節因子
WO2010037224A1 (fr) 2008-10-03 2010-04-08 St. Michael's Hospital Procédé de prévention et de traitement de maladies cardiovasculaires avec brca1

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIN GAO ET AL: "Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 488, no. 3, 5 January 2001 (2001-01-05), pages 179 - 184, XP004337942, ISSN: 0014-5793 *
HORVATH C M: "STAT proteins and transcriptional responses to extracellular signals", TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 25, no. 10, 1 October 2000 (2000-10-01), pages 496 - 502, XP004224290, ISSN: 0968-0004 *
JACQUELINE BROMBERG: "SIgnal transducers and activators of transcription as regulators of growth, apoptosis and breast development.", BREAST CANCER RES., vol. 2, 2000, pages 86 - 90, XP002902723 *
ROBYN CATLETT-FALCONE ET AL: "STAT proteins as novel targets for cancer therapy", CURRENT OPINION IN ONCOLOGY, vol. 11, 1999, pages 490 - 496, XP002902722, ISSN: 1040-8746 *
TORU OUCHI ET AL: "Collaboration of signal transducer and activator of transcription 1(STAT1) and BRCA1 in differential regulation of IFN- gamma target genes.", PROC. NATL ACAD. SCI., vol. 97, no. 10, 9 May 2000 (2000-05-09), USA, pages 5208 - 5213, XP002902721 *

Also Published As

Publication number Publication date
WO2002046466A2 (fr) 2002-06-13
AU2002233572A1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
Triulzi et al. FOXP3 expression in tumor cells and implications for cancer progression
Kim et al. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy
Zhou et al. Up-regulation of SERPINA3 correlates with high mortality of melanoma patients and increased migration and invasion of cancer cells
ATE354588T1 (de) Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden
AU6275799A (en) Ykl-40 as a marker and prognostic indicator for cancers
WO2000024933A8 (fr) Detection de la perte d'heterozygosite dans les tumeurs et le serum de patients atteints de melanome
WO2005032343A3 (fr) Signalisation hedgehog dans la regeneration, la neoplasie et la metastase prostatique
RU2013146242A (ru) Fgfr и его лиганды в качестве биомаркеров рака молочной железы у hr-положительных индивидуумов
Badenas et al. Genetic counseling in melanoma
EA200970108A1 (ru) Композиции и способы для ингибирования роста smad4-дефицитных форм рака
Welinsky et al. Familial pancreatic cancer and the future of directed screening
WO1999058139A3 (fr) Procedes de detection et d'inhibition de l'angiogenese
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
Ma et al. Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma
PH12022552766A1 (en) Method for early detection, prediction of treatment response and prognosis of colorectal cancer
WO2006015383A3 (fr) Biomarqueurs de diagnostic, pronostic, controle et decisions de traitement pour la pharmacoresistance et la sensibilite aux medicaments
Sameer et al. Epigenetics in diagnosis of colorectal cancer
WO2002046466A3 (fr) Complexes de polypeptides de brca et de stat et procedes d'utilisation dans la detection et le traitement du cancer
WO2000065067A3 (fr) Polynucleotides, polypeptides specifiques a la prostate, et leurs procedes d'utilisation
EP2199801A3 (fr) Biomarqueurs pour la détection précoce du cancer des ovaires
Iwasaki et al. Over-expression of PDE5 in Oral Squamous Cell Carcinoma–Effect of Sildenafil Citrate
NO982588D0 (no) FremgangsmÕte for diagnose og behandling av plate epizelkarsinom
SE9902608D0 (sv) Histamine detection and detector
Sørensen et al. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer
Atzmony et al. Stage-dependent increase in expression of mir-155 and ki-67 and number of tumour-associated inflammatory cells in folliculotropic mycosis fungoides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP